Friday, 13 November 2026European Markets

Euro Hits 14% Annual Gain as Dollar Slides to 2022 Lows, Testing ECB Policy Stance

The euro surged 14% in 2025 while the dollar fell to its lowest level since 2022, creating headwinds for European exporters ahead of critical policy decisions. The British pound gained 7% over the same period, with the Swiss franc also strengthening. Fed leadership changes in June and progress on Iran-US nuclear negotiations are adding volatility to currency markets.

From our archive, published before source-traceability. How we work

Euro Hits 14% Annual Gain as Dollar Slides to 2022 Lows, Testing ECB Policy Stance
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro has climbed 14% against the dollar over 2025 as the US currency tumbled to levels last seen in 2022, forcing European policymakers to weigh competitiveness concerns against the benefits of cheaper imports.

The British pound rose 7% against the dollar in 2025, with sterling trading at $1.3086 in late February 2026 despite falling 0.5% in recent sessions. The Swiss franc has also strengthened significantly during the dollar's decline.

European exporters face margin pressure from the euro's strength, which makes EU goods more expensive for international buyers. The currency shift arrives as the European Central Bank navigates inflation targets and growth concerns across member states with varying economic conditions.

The dollar weakness precedes a Federal Reserve leadership transition scheduled for June, creating uncertainty about US monetary policy direction. Markets are pricing in potential strategy shifts that could extend or reverse the dollar's current trajectory.

Progress on Iran-US nuclear deal negotiations has added volatility to commodity-linked currencies, with oil markets responding to potential sanctions relief. WTI crude traded around $61 per barrel in mid-February, up 1.5% in a single session, while Brent crude held above $65.

UK gilt yields climbed to 5.21% for 30-year bonds, the highest since 1998 peaks in August, as Chancellor Rachel Reeves prepares her November 26 budget. The UK issues roughly 25% of its debt in inflation-linked bonds compared to 10% in the US and France, making British borrowing costs particularly sensitive to price pressures.

Currency analyst Jordan Rochester at Mizuho Bank warned the pound could fall below $1.30 if fiscal concerns intensify. Simon Phillips at No1 Currency noted pressure on sterling from both fiscal and monetary policy uncertainty.

The European Stoxx 600 reached a record 583.4 points in mid-February, up 0.6%, while Germany's DAX gained 0.9%. Strong equity performance suggests investors view euro strength as manageable rather than crisis-inducing, contrasting with past episodes of sharp currency appreciation.

Gold prices climbed above $4,100 per ounce as investors sought alternatives to dollar-denominated assets. The precious metal's rally reflects broader concerns about US fiscal sustainability and currency depreciation risks.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com